While gut health is no longer a taboo topic, consumer understanding of the key role of the gut and microbiome on general well-being is still not understood. Developing successful products for this category requires an understanding of the gut microflora and its impact on health issues, as well as communication strategies. Gain an insight into the trends in the probiotics market; the regulatory considerations to be addressed in product development and launch; and the importance of selecting appropriate strains for specific health benefits.
Digital summits are a new experience in online education, optimized for professionals who need deeper dive information to help them make key business decisions. These immersive education programs are presented by thought leaders in the probiotics industry, addressing the industry's top challenges.
As a registered user, you can attend the live event on Dec. 2nd to view video content in real time with live Q and A interaction with the presenters, or you can watch the content on-demand after the live event.
Inside the Digital Summit platform, users have access to a resource library featuring premium content from INSIDER, along with whitepapers, briefs, and webinar content from the event underwriters. You'll have the ability to create your own profile, pose questions, start a dialogue, download resource material and much more.
Recent advances in genomics technologies and bioinformatics has enabled researchers to study the entire gut microbial community and elucidate its role in human health. We will discuss how these approaches allow us to now study the effects of probiotics on the gut microbiome and what research has shown thus far.
The concept of probiotics, which was introduced in the early 20th century, has recently gained considerable importance in the health-food industries across the world. Given its significance in dietary supplements and in dairy products, it is predicted to grow at the rate of 7.7% from 2012 to 2020. Such staggering rise in the use of probiotics in the global market warrants the implementation of a common regulatory measure for all the regions/countries. To meet this challenge, FAO/WHO has recently introduced the guidelines and recommended criteria for the evaluation of probiotics. One of the recommendations is to identify the genus and species of the probiotic strain used. Further, since clinical evidence suggests the health benefit of probiotics is likely to be strain-specific, it is crucial to identify the strains in each dairy/health related-food product. Although the current recommended molecular techniques, such as 16S rDNA sequencing, can accurately identify to the species level, methods such as Ribotyping and Pulsed Field Gel Electrophoresis (PFGE) are unlikely to yield accurate strain-level identification. Utilizing these previously recommended methods as well as using two additional methods, MALDI-TOF and Multilocus Sequence Typing (MLST), the present study endeavored to identify the probiotic strains from commercially available yogurt brands and evaluated the ability of different identification platforms for species and strain-level characterization.
The market for probiotics is growing and the applications for probiotics are increasingly expanding. With such diverse beneficial applications for probiotics and so many different options for product consumption, market possibilities seem endless. However, it is important to consider the regulatory limitations for probiotics when marketed as a supplement, functional food or beverage, OTC or drug. Dietary supplements, by definition, are meant to "supplement the diet" in order to maintain a healthy body and mind. Probiotics confer many diverse health benefits, which raises the question: do probiotics technically "fit" within the confines of the dietary supplement definition? This session will present the most recent regulatory guidance on probiotics, and compare efficacy claims substantiation needed for probiotics as a food or as a supplement, as well as how subtle changes to marketing claims may position a probiotic as a drug in the eyes of FDA and FTC.
The EU probiotic claim ban continues to constrain the pro/prebiotic drinking yogurt market in Austria, Belgium, France, Germany, Netherlands and the United Kingdom. Using Euromonitor International’s preliminary research data based on the forthcoming 2016 edition of Health and Wellness and the Industry Demand Model, Euromonitor estimates the ban has already cost the pro/prebiotic drinking yoghurt market over EUR500 million in lost retail value sales since 2012 in these countries. Between 2015 and 2020, this market stands to lose a further EUR1 billion in retail value as result of the ban of probiotic claims.
Ewa Hudson manages the research program for the global health and wellness industry at Euromonitor International, which she joined in March 2003. In her current post, Hudson has direct responsibility over the content and quality of Euromonitor’s Health and Wellness Food and Beverages research. She is also responsible for working with the international client base of Euromonitor’s online Health and Wellness Foods and Beverages Passport. Before joining Euromonitor, Hudson worked as a senior analyst for Snapshots International, overseeing consumer market research for Eastern Europe, the United Kingdom and the United States. She has a master’s degree in economics from the University of Poznan, Poland, and has also studied postgraduate marketing at the University of Westminster in London.
Sunita Kumar is a multi-prong entrepreneur and the founder of Nourish Nutrition Inc. After spending more than a decade at leading consumer brands and agencies launching products and campaigns for companies such as L’Oreal, American Express, Intuit, Visa, Amazon and Sprout Organic Foods, Kumar now brings her expertise as a scientist and marketer, along with her background in product formulation, supply chain and health-focused retail, to companies looking for guidance on trends, ingredient formulation and advice how to optimize their retail story to drive business growth.
Ray A. Matulka, Ph.D. is the director of toxicology at Burdock Group, bringing more than a decade of experience in the analysis of toxicity data and conducting safety and risk assessments. He earned a doctorate in toxicology from the Medical College of Virginia, and has post-doctoral experience at both Boston University School of Medicine and the University of North Carolina. He has industry experience at the Nebraska Dept. of Environmental Control and as a senior genetic toxicologist at Genesys Research in North Carolina. He is co-author of two book chapters and has authored 20 publications since obtaining his doctoral degree. Dr. Matulka has experience presenting information to the FDA, USDA and EPA. Among other responsibilities, Dr. Matulka is accountable for the development of consumption analysis and reporting, and offers guidance in strategic scientific business planning and critical decision making to Burdock Group clients in the food ingredient, health and nutrition industries.
Take Ogawa is a director at Second Genome, a leading provider of end-to-end solutions for profiling the human microbiome, based in South San Francisco, California. He has spent the last 15 years in life sciences developing and promoting genomics tools and applications. Ogawa was part of the development team that launched the first high-throughout DNA sequencer at Applied Biosystems (now Thermo Fisher Scientific) that was responsible for sequencing the first human genome. He also promoted the first next-generation sequencing platform at 454/Roche.
Bindhu Verghese completed her doctorate degree in biological science from the University of Tulsa. After three years of post-docorate work at Pennsylvania State University’s Food Science Dept., she joined as R&D senior staff scientist in endotoxin and microbial detection at Charles River in Newark, Delaware. She has 10 years’ experience of conducting research using molecular and microbial techniques. In her current role, she is involved in developing new assays, evaluating new technologies and coordinating research studies.